Overview
- Australia’s medicines regulator warned that unapproved peptides have not been assessed for safety, quality or efficacy and may be contaminated or mislabelled.
- Clinicians report escalating interest and use, with one GP saying patients as young as 14 have accessed injectable peptides online.
- Experts note that most anti-ageing and performance peptides touted on social media lack robust human data, whereas medicines like GLP-1 drugs and insulin are evidence-based and approved.
- Quality concerns are mounting, with lab checks finding some products mislabelled and reports that about 12% of tested vials contained bacterial endotoxins.
- The peptide therapeutics market is growing quickly, U.S. rules have restricted pharmacy compounding since 2023, and HHS Secretary Robert F. Kennedy Jr. has said he plans steps to expand access.